Vor Bio expands RemeGen deal to add long-acting BAFF/APRIL drug RC298
Vor Bio amended its license with RemeGen to include RC298, paying $10 million cash plus warrants, with up to $300 million more tied to milestones.
SEC filing
2 stories
Vor Bio amended its license with RemeGen to include RC298, paying $10 million cash plus warrants, with up to $300 million more tied to milestones.
SEC filing
Vor filed a prospectus supplement on October 30, 2026 to sell shares through William Blair and RBC Capital Markets after its prior $125 million Stifel agreement expired.
SEC filing